BMRN Stock Analysis: Buy, Sell, or Hold?
BMRN - BioMarin Pharmaceuticals Inc
$60.55
1.22 (2.06%)
▲
5d:
+2.44%
30d:
+5.58%
90d:
+13.86%
BUY
MODERATE Confidence
Analysis Updated: Jul 24, 2026 12:00 AM ET
Earnings: Aug 03, 2026
6d
Smart Money Accumulation
None View Scanner →
Strength: 4.9/10
Get Alerted When BMRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 0.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BMRN shows positive signals but monitor for confirmation. Market pricing in 0.4% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$117.06
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$72.68
16.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 9.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BMRN is currently trading at $60.55, which is considered slightly high relative to its 30-day fair value range of $56.52 to $59.74. The stock's valuation (Forward PE: 9.3) is in line with its historical norms (9.4). Remarkably, the market is currently pricing in an annual earnings decline of 0.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BMRN is in a uptrend. The price is approaching resistance at $60.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $87.92 (+48.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BMRN is in a uptrend. The price is approaching resistance at $60.64. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $87.92 (+48.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$56.52 -
$59.74
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 48.2% below Wall St target ($87.92)
Trading Range Analysis
30-Day Trading Range
$56.52 -
$59.74
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$57.42
Resistance Level
$60.64
Current Trend
Uptrend
Technical data as of
Jul 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.28
Wall Street Target
$87.92
(+48.2%)
Revenue Growth (YoY)
2.8%
Earnings Growth (YoY)
-43.1%
Profit Margin
8.3%
Valuation Discount vs History
-0.4% cheaper
PE vs Historical
9.3 vs 9.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.4%
(market-implied from PE analysis)
1-Year Target
$59.09
(0%)
2-Year Target
$58.86
(-1%)
3-Year Target
$58.62
(-1%)
3-Yr Target (if PE normalizes)
(PE: 9→9)
$59.39
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.8, Growth: 29.6%)
$289.62
(+388%)
Base:
(SPY PE: 9.3, Growth: 29.6%)
$129.12
(+118%)
Bear:
(PE: 7.9, Growth: 29.6%)
$109.76
(+85%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (42x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 42.35 | Current EPS (TTM): $1.39
Bull Case
$129.51
(+118%)
Analyst growth 100.0%, PE expands to 46.6
Base Case
$117.74
(+98%)
Market implied 100.0%, PE stable at 42.4
Bear Case
$40.03
(-33%)
Severe decline -20.0%, PE contracts to 36.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.3 to 9.4
Stabilization Target:
$60.11
(+1.3%)
PE Expansion Potential:
+1.3%
Share & Embed Analysis
Last updated: July 27, 2026 10:21 AM ET
Data refreshes hourly during market hours. Next update: 11:21 AM
Data refreshes hourly during market hours. Next update: 11:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles Greg Guyer
SELL
16486 shares
2026-03-11
Gregory R Friberg
SELL
6326 shares
2026-02-26
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 53 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 57 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 51 HOLD |
|
CNTA
Centessa Pharmaceuticals… |
STRONG BUY
11 analysts |
$44 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$39 | 53 HOLD |
Advanced BMRN Option Strategies
Professional options setups generated by AI based on today's BMRN price and gamma walls.
